← Back to patent-cliff list
Gemcitabine Hydrochloride/Docetaxel
Tier C — Watch / tradeGemcitabine Hydrochloride/Docetaxel
Trigone Pharma Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DNA, RNR, Tubulin
Indications (approved)：Bladder cancer, Urinary tract neoplasm, 转移性上皮癌
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Gemcitabine Hydrochloride/Docetaxel?
Approved indications include: Bladder cancer, Urinary tract neoplasm, 转移性上皮癌.
When does the Gemcitabine Hydrochloride/Docetaxel patent expire?
No public expiry year is available for Gemcitabine Hydrochloride/Docetaxel yet; this page updates once verified.
How do I get a quote for Gemcitabine Hydrochloride/Docetaxel intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29